Association between Henoch-Schonlein purpura and Helicobacter pylori infection is rarely reported in the literature. We present a case of Henoch-Schonlein purpura with severe gastrointestinal manifestations, bradycardia and euthyroid sick syndrome, were resolution of disease occurred only after the eradication of Helicobacter pylori infection.
INTRODUCTION
Henoch-Schönlein purpura (HSP) is the most common systemic vasculitis in children ( 10 -30 cases per 100,000 children under 17 years) and usually occurs in children younger than 10 years (1). HSP is non-granulomatous, small-vessel vasculitis, which presents with palpable purpura on the lower extremities and buttocks with possible joint, gastrointestinal and renal involvement 1 . In 75% of patients, an infection precedes HSP (2) . Helicobacter pylori (HP) infection is rarely associated with HSP.
We present a case of HSP with severe gastrointestinal manifestations, bradycardia and euthyroid sick syndrome, were resolution of disease occurred after the eradication of Helicobacter pylori infection.
CASE REPORT
A five-year old boy was hospitalized due to palpable purpura, abdominal pain and vomiting.
The disease began four days earlier with petechial rash on the legs, followed by episodes of abdominal pain and vomiting. He was previously healthy.
On admission, he had palpable purpura on the legs and gluteus, and feet oedema. Our diagnosis was HSP, so we started the therapy with methylprednisolone (1 mg/kg/day) and proton pump inhibitor. On the 3 rd day, palpable purpura re-emerged, now affecting all four extremities. This was accompanied by intense abdominal pain, colicae, diarrhoea and haematochezia. Ultrasound examination of the abdomen showed advanced thickening of intestinal walls. Due to exacerbation of the disease, we administered methylprednisolone pulse therapy (30 mg/kg/day) during 3 days, and then proceed with methylprednisolone at standard dose of 1mg/kg/day. Oral intake has been suspended and total parenteral nutrition was initiated.
All these therapeutic measures gave only a short-term effect.
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On the 9 th day, previous symptoms relapsed. Ultrasonography revealed further thickening of the intestinal walls. Intravenous immunoglobulins (IVIG) 2 g/kg, were given. This was followed by significant clinical improvement, but, in attempts to reduce the doses of corticosteroids, abdominal pain and skin lesions relapsed.
During the 3 rd week of illness, the boy become bradycardic (heart rate 44/min) and constipated.
Standard ECG showed sinus bradycardia. 24h ECG Holter monitoring showed persistent bradycardia with mean heart rate of 55/min, minimal heart rate of 39/min, without significant sinus pauses and conduction disorders ( Figure 2 ). Echocardiography was normal. In our patient, the course of disease was complicated with persistent bradycardia. There are few described cases of adult patients treated with methylprednisolone, in whom bradycardia emerged within a few hours to several days after the start of the therapy. Also, in patients treated with conventional lower doses of corticosteroids, episodes of bradycardia were reported, but, extremely rarely (9) . The mechanisms by which corticosteroids may cause bradycardia have not been fully elucidated, but there are few speculations, such are that corticosteroids directly affect cardiomyocytes modulating their sensitivity to catecholamines, or cause rapid electrolyte shifts across cell membranes, or indirectly -by inducing arterial hypertension. But, in our patient, likely cause of bradycardia were decreased T3 levels.
Possible mechanisms of decreased T3 availability may be corticosteroid-induced block of peripheral conversion of T4 to T3 or competition between corticosteroids and thyroid hormones for albumin binding sites what decreases T3 levels despite normal T4 levels (10).
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